Search | Clinical Trials Finder

Conditions: Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
Interventions: Cyclobenzaprine HCl, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: Arthroplasty, Replacement, Knee, Sleep Initiation and Maintenance Disorders
Interventions: Melatonin 5 mg, Placebo (Vitamin C); Dietary Supplement
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibromyalgia
Interventions: TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Phoenix, Arizona • Oceanside, California • Santa Ana, California + 30 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Mifepristone Oral Tablet [Korlym], Placebo Oral Tablet; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: San Diego, California • Albuquerque, New Mexico • The Bronx, New York + 2 more

Conditions: Multiple Sclerosis, Fatigue, Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Theodore R. Brown, MD MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: volinanserin (M100907), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Insomnia Disorder
Interventions: Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Crestview Hills, Kentucky

Conditions: Restless Legs Syndrome
Interventions: rasagiline, placebo (sugar pill); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Pinellas Park, Florida • Augusta, Georgia • Chicago, Illinois + 5 more

Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions: Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more

Conditions: Obstructive Sleep Apnea, Healthy Subjects
Interventions: Placebo, Lemborexant 10 mg, Lemborexant 25 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 11
States / cities: Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more

Conditions: OSA
Interventions: AD109, Placebo; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 65
States / cities: Tuscaloosa, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Sexual Dysfunctions, Psychological, Depression
Interventions: flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 42
States / cities: Costa Mesa, California • Fresno, California • National City, California + 36 more

Conditions: Unipolar Depression
Interventions: lamotrigine, placebo, paroxetine; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cirrhosis
Interventions: Placebo Oral Tablet, Simvastatin 40mg; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: San Francisco, California • West Haven, Connecticut • Louisville, Kentucky + 7 more

Conditions: Obesity, Prediabetic State
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Depression
Interventions: Asenapine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Bipolar Depression
Interventions: quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride; Drug
Lead sponsor: Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: San Diego, California • Kirkland, Washington

Conditions: Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions: Topiramate, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: PTSD
Interventions: TNX-102 SL, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more

Conditions: Healthy Volunteers
Interventions: TS-142, TS-142 Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cancer Malignancies
Interventions: melatonin, placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Mammographic Density, Abnormal Mammogram
Interventions: CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 517 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, HIV Infections
Interventions: Stribild, Atripla, Stribild Placebo, Atripla Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 97
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more

Search by objective public record fields.

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

TKA Melatonin and Sleep Quality

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

RECOVER-SLEEP: Platform Protocol

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Lamotrigine Augmentation in Resistant Depression

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

Effect of Melatonin on Cardiometabolic Risk- FULL

Asenapine for Bipolar Depression

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort

KEEPS Mammographic Density And Breast Health Ancillary Study

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults